Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis

Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens. We hypothesized that both modifications, i.e., the addition of clofazimine and the replacement of rifampin with high-dose rifapen...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Saini, Vikram, Ammerman, Nicole C., Chang, Yong Seok, Tasneen, Rokeya, Chaisson, Richard E., Jain, Sanjay, Nuermberger, Eric, Grosset, Jacques H.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2019
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535519/
https://ncbi.nlm.nih.gov/pubmed/30936097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00388-19
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires